TY - JOUR
T1 - White matter hyperintensities precede other biomarkers in GRN frontotemporal dementia
AU - Soltaninejad, Mahdie
AU - Dadar, Mahsa
AU - Collins, D. Louis
AU - Rajabli, Reza
AU - Venkatraghavan, Vikram
AU - Bouzigues, Arabella
AU - Russell, Lucy L.
AU - Foster, Phoebe H.
AU - Ferry-Bolder, Eve
AU - van Swieten, John C.
AU - Jiskoot, Lize C.
AU - Seelaar, Harro
AU - Sanchez-Valle, Raquel
AU - Laforce, Robert
AU - Graff, Caroline
AU - Galimberti, Daniela
AU - Vandenberghe, Rik
AU - de Mendonça, Alexandre
AU - Tiraboschi, Pietro
AU - Santana, Isabel
AU - Gerhard, Alexander
AU - Levin, Johannes
AU - Nacmias, Benedetta
AU - Otto, Markus
AU - Bertoux, Maxime
AU - Lebouvier, Thibaud
AU - Butler, Chris R.
AU - Ber, Isabelle Le
AU - Finger, Elizabeth
AU - Tartaglia, Maria Carmela
AU - Masellis, Mario
AU - Rowe, James B.
AU - Synofzik, Matthis
AU - Moreno, Fermin
AU - GENFI consortium
AU - Borroni, Barbara
AU - Rohrer, Jonathan D.
AU - Iturria-Medina, Yasser
AU - Ducharme, Simon
N1 - Publisher Copyright:
© 2025 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2025/10/1
Y1 - 2025/10/1
N2 - INTRODUCTION: Increased white matter hyperintensities (WMHs) have been reported in genetic frontotemporal dementia (FTD) in small studies, but the sequence of WMH abnormalities relative to other biomarkers is unclear. METHODS: Using a large dataset (n = 763 GENFI2 participants), we measured WMHs and examined them across genetic FTD variants and stages. Cortical and subcortical volumes were parcellated, and serum neurofilament light chain (NfL) levels were measured. Biomarker progression was assessed with discriminative event-based and regression modeling. RESULTS: Symptomatic GRN carriers showed elevated WMHs, primarily in the frontal lobe, while no significant increase was observed in symptomatic C9orf72 or MAPT carriers. WMH abnormalities preceded NfL elevation, ventricular enlargement, and cortical atrophy. Longitudinally, baseline WMHs predicted subcortical changes, while subcortical volumes did not predict WMH changes, suggesting WMHs may precede neurodegeneration. DISCUSSION: WMHs are elevated in a subset of GRN-associated FTD. When present, they appear early and should be considered in disease progression models. Highlights: Elevated WMH volumes are found predominantly in symptomatic GRN. WMH accumulation is mostly observed in the frontal lobe. WMH abnormalities appear early in GRN-associated FTD, before NfL, atrophy, and ventriculomegaly. Longitudinally, WMH volumes can predict subcortical changes, but not vice versa. WMHs are key early markers in GRN-associated FTD and should be included in progression models.
AB - INTRODUCTION: Increased white matter hyperintensities (WMHs) have been reported in genetic frontotemporal dementia (FTD) in small studies, but the sequence of WMH abnormalities relative to other biomarkers is unclear. METHODS: Using a large dataset (n = 763 GENFI2 participants), we measured WMHs and examined them across genetic FTD variants and stages. Cortical and subcortical volumes were parcellated, and serum neurofilament light chain (NfL) levels were measured. Biomarker progression was assessed with discriminative event-based and regression modeling. RESULTS: Symptomatic GRN carriers showed elevated WMHs, primarily in the frontal lobe, while no significant increase was observed in symptomatic C9orf72 or MAPT carriers. WMH abnormalities preceded NfL elevation, ventricular enlargement, and cortical atrophy. Longitudinally, baseline WMHs predicted subcortical changes, while subcortical volumes did not predict WMH changes, suggesting WMHs may precede neurodegeneration. DISCUSSION: WMHs are elevated in a subset of GRN-associated FTD. When present, they appear early and should be considered in disease progression models. Highlights: Elevated WMH volumes are found predominantly in symptomatic GRN. WMH accumulation is mostly observed in the frontal lobe. WMH abnormalities appear early in GRN-associated FTD, before NfL, atrophy, and ventriculomegaly. Longitudinally, WMH volumes can predict subcortical changes, but not vice versa. WMHs are key early markers in GRN-associated FTD and should be included in progression models.
KW - C9orf72
KW - FTD
KW - GRN
KW - MAPT
KW - biomarker sequence
KW - dementia
KW - disease progression
KW - early marker
KW - event-based modeling
KW - magnetic resonance imaging
KW - neurodegeneration
KW - neurofilament light chain
KW - neuroimaging
KW - progranulin
KW - white matter
UR - https://www.scopus.com/pages/publications/105017934699
U2 - 10.1002/alz.70695
DO - 10.1002/alz.70695
M3 - Article
C2 - 41057914
SN - 1552-5260
VL - 21
JO - Alzheimer s & dementia
JF - Alzheimer s & dementia
IS - 10
M1 - e70695
ER -